decisionhealth Newsletters, Part B News - 2018 Issue 1 (January)
At hearing, Azar open to mandatory bundled programs, drug price deals
Subscribe or sign in to view the full article.
Article Overview
This premium article covers remarks made during Alex Azar’s Senate Finance Committee hearing and the health policy areas he addressed. It is relevant to readers tracking Medicare innovation models, drug pricing policy, Medicaid financing proposals, Medicare program sustainability, and transparency initiatives discussed in a confirmation context.
Why This Topic Matters
The article helps policy, health care, and reimbursement readers understand how a potential HHS leader framed major federal health program issues that can influence payment policy, drug pricing strategy, and future CMS direction.
What You Will Learn
- The general policy areas discussed during the Senate hearing
- How the hearing touched on Medicare innovation and payment reform
- What was said about prescription drug pricing and negotiation
- How Medicaid financing and state flexibility were framed
- Which broader health policy topics were raised in the confirmation discussion
Who Should Read This
- Health care policy professionals
- Medical billing and coding leaders
- Payer and reimbursement analysts
- Hospital and health system administrators
- Pharmaceutical policy stakeholders
- Government affairs professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com